Results 291 to 300 of about 1,591,450 (336)
Some of the next articles are maybe not open access.
Current Opinion in Oncology, 1996
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
Breast Cancer Treatment: A Review
Journal of the American Medical Association (JAMA), 2019Importance Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and
Adrienne G. Waks, E. Winer
semanticscholar +1 more source
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
New England Journal of MedicineBACKGROUND Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of ...
A. Bardia +18 more
semanticscholar +1 more source
Curing Metastatic Breast Cancer
Journal of Oncology Practice, 2016Metastatic breast cancer is generally considered incurable, and this colors doctor-patient interactions for patients with metastatic disease. Although true for most patients, there appear to be important exceptions, instances where long-term disease-free survival occurs. Although these instances are few in number, they suggest the possibility of cure.
openaire +2 more sources
CTCs in Metastatic Breast Cancer
2012Circulating tumor cells (CTCs), enumerated by the Food and Drugs Administration-cleared CellSearch(®) system, are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients.
Giordano A., Cristofanilli M.
openaire +3 more sources
Cutaneous Metastatic Breast Cancer
Clinical Journal of Oncology Nursing, 2002Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer deaths among women in the United States. Many women diagnosed with breast cancer will achieve a cure with surgery followed by adjuvant chemotherapy, hormonal therapy, or radiation therapy; however, some breast cancer survivors will develop locally ...
openaire +2 more sources
2019
De novo Stage IV breast cancer compromises 5–6% of woman with breast cancer. Systemic staging at the time of initial presentation is recommended for patients with clinical Stage IIIA disease or patients who have symptoms concerning for metastatic disease. Patients were suspected to have metastatic disease should be referred to medical oncology.
Zeynep Bostanci, Laura Kruper
openaire +2 more sources
De novo Stage IV breast cancer compromises 5–6% of woman with breast cancer. Systemic staging at the time of initial presentation is recommended for patients with clinical Stage IIIA disease or patients who have symptoms concerning for metastatic disease. Patients were suspected to have metastatic disease should be referred to medical oncology.
Zeynep Bostanci, Laura Kruper
openaire +2 more sources
2010
Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative.
Tejal A. Patel, Edith A. Perez
openaire +1 more source
Metastatic breast cancer is a leading cause of morbidity and mortality that needs to be understood and conquered. Although fewer than 10% of patients with breast cancer initially present with the metastatic disease, it will eventually develop in a substantial proportion of them [1]. Therapy for metastatic breast cancer remains palliative.
Tejal A. Patel, Edith A. Perez
openaire +1 more source
2016
This chapter is a review of the current evidence for managing metastatic breast cancer. The treatment of metastatic disease is a complex one when compared to the early setting for which there is clear and high level of evidence. There has been a constant effort to improve survival in metastatic patients, but the incurable nature of the disease, its ...
Berta Sousa +3 more
openaire +1 more source
This chapter is a review of the current evidence for managing metastatic breast cancer. The treatment of metastatic disease is a complex one when compared to the early setting for which there is clear and high level of evidence. There has been a constant effort to improve survival in metastatic patients, but the incurable nature of the disease, its ...
Berta Sousa +3 more
openaire +1 more source
New England Journal of Medicine, 1991
WITHIN the young discipline of medical oncology, the systemic therapy of metastatic breast cancer has a long history.
openaire +1 more source
WITHIN the young discipline of medical oncology, the systemic therapy of metastatic breast cancer has a long history.
openaire +1 more source